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Abstract
Angioinvasion is critical for metastasis with urokinase-type plasminogen activator receptor (uPAR) and tumor hypoxia-
activated hypoxia-inducible factor 1 (HIF-1) as key players. Transcriptional control of uPAR expression by HIF has never
been reported. The aim of the present study, therefore, was to test whether tumor hypoxia-induced HIF expression
may be linked to transcriptional activation of uPAR and dependent angioinvasion. We used human pancreatic cancer
cells and a model of parental and derived HIF-1β–deficient mouse liver cancer cell lines and performed Northern blot
analysis, nuclear runoff assays, electrophoreticmobility shift assay, polymerase chain reaction–generated deletionmu-
tants, luciferase assays,Matrigel invasion assays, and in vivo angioinvasion assays in the chorioallantoicmembrane of
fertilized chicken eggs. Urokinase-type plasminogen activator receptor promoter analysis resulted in four putative HIF
binding sites. Hypoxia strongly induced de novo transcription of uPARmRNA.With sequential deletionmutants of the
uPAR promoter, it was possible to identify one HIF binding site causing a nearly 200-fold increase in luciferase activity.
Hypoxia enhanced the number of invading tumor cells in vitro and in vivo. In contrast, HIF-1β–deficient cells failed to
upregulate uPAR expression, to activate luciferase activity, and to invade on hypoxia. Taken together, we show for the
first time that uPAR is under transcriptional control of HIF and that this is important for hypoxia-induced metastasis.
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Introduction
A hypoxic microenvironment of low oxygen is found in solid tumors
including pancreatic cancer [1]. It is associated with restrained cell
proliferation and it promotes tumor aggressiveness and acquired re-
sistance to treatment [2,3]. The latter occurs as a direct result of re-
duced generation of free radicals and by the reduction of fixation of
radiation-induced DNA damage [1,4]. Clinically, tumor hypoxia oc-
curs heterogeneously within the tumor mass and is independent of
tumor size, stage, histologic diagnosis, and tumor grade [5–7]. It has
been suggested that hypoxia selects for more malignant cell clones,
that is, by promoting those with diminished apoptotic potential
owing to p53 alterations [8] or, for example, by activating adenosine
A(3) receptor–Akt pathway, which mediates Bad inactivation and
favors cell survival [9,10]. Furthermore, hypoxia was shown to select
for cell clones with reduced E-cadherin expression and, therefore,
promotes tumor cell metastasis [11–13]. Hypoxia also promotes
adaptive processes associated with metabolic adaptation, improved
systemic oxygen supply, cell survival, and cell proliferation [14].
Hypoxia-inducible factor 1 (HIF) is a transcriptional activator that
functions as a master regulator of oxygen homeostasis in all metazoan
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species. It is a heterodimeric protein composed of a constitutively ex-
pressed HIF-1β subunit and an oxygen-regulated HIF-1α subunit
[15]. Transcriptional activation of HIF-1 and HIF-2 in hypoxia
is mediated by the inhibition of asparagine-hydroxylase HIF-1 that
in normoxia hydroxylates the HIF-1α C-terminal activation domain,
precluding thus interaction with transcriptional coactivators p300/
CBP [16–18]. Inhibition of prolyl hydroxylases in hypoxia also af-
fects the stability of HIF-1α [19,20]. One hydroxylated binding of
the von Hippel-Lindau (VHL) protein [21] results in ubiquitination
and proteasomal degradation [22]. Under hypoxic conditions, the
rate of hydroxylation declines, leading to HIF activation and thus
providing a mechanism by which changes in oxygenation are trans-
duced to the nucleus as changes in gene expression [23].
Previous studies have demonstrated that HIF transactivates genes
involved in energy metabolism, involving glucose transporters and
glycolytic enzymes in response to reduced oxygen availability [24].
Other known target genes of HIF play an important role in angio-
genesis, erythropoiesis, cell proliferation, and vasomotor responses
[14]. Although the role of HIF in angiogenesis is well characterized
[25], the function of this transcription factor in uPAR-mediated in-
vasion and metastasis is less clear and not examined in detail [26].
Available data suggest that tumor cells need to migrate across tissue
barriers and gain access to systemic circulation to be disseminated to
metastatic organs [27]. During this multistep process, tumor cells de-
tach from the primary tumor and invade tumor blood vessels (intra-
vasation) which they finally extravasate to metastasize in organs
(extravasation) where they form the secondary lesion. Dissemination
occurs through blood or lymphatic circulation breaching of the vas-
culature wall, and this seems to be the crucial rate-limiting event dur-
ing metastasis [27,28]. This concept is simple, although it is not
known why only some but not all cells of a clonal tumor population
acquire the ability to cross tissue borders. Some of the players within
the initial scenario of intravasation have been identified, and the pre-
dominant protease system, which apparently regulates angioinvasion,
seems to involve the system of urokinase-type plasminogen activator
(uPA) and its receptor (uPAR) [27,29].
Urokinase-type plasminogen activator receptor is a three-domain
(D1-3) glycosyl phosphatidylinositol–anchored cell surface receptor
with a high affinity for uPA, pro-uPA, and ATF [30,31]. Urokinase-
type plasminogen activator receptor can be released from the plasma
membrane by cleavage of the glycosyl phosphatidylinositol anchor and
is then found as a soluble molecule (suPAR). Intact uPAR binds uPA
with high affinity but can also bind vitronectin and members of the
integrin family [32,33]. Bound uPAR is found at focal adhesion sites,
yet the cellular mechanisms of signal transduction is unknown [32,34].
So far, at least three transmembrane proteins have been identified to
be targeted by uPAR: integrins, G protein–coupled receptors, and
caveolin [30,35]. Control of uPAR transcription is located within
the first 400 bp upstream of the transcription initiation site driven
by a nonspecified TATA-less promoter [36]. Despite recent reports in-
dicating a correlation between hypoxia-induced up-regulation of uPAR
and uPA levels and a bad prognosis for patient survival in pancreatic
cancer [37], transcriptional regulation of the human uPAR promoter
by HIF has never been examined.
In the present study, we identified uPAR gene as a novel target
gene transcriptionally regulated by HIF. We show that hypoxia reg-
ulates tumor cell angioinvasion and metastasis through activation of
HIF and transcriptional up-regulation of uPAR, the main mediator
in tumor cell invasion. Our data establish a molecular link between
the clinical observation of increased tumor aggressiveness and tumor
hypoxia in pancreatic and liver cancer cells.
Materials and Methods
Cell Lines
Human pancreatic cell lines AsPc-1, Capan-2, MIA PaCa-2, and
PANC-1 were purchased from the American Tissue Type Culture
Collection (ATCC, Rockville, MD). Parental mouse hepatoma cells
Hepa-1c1c7 and the derived mutant c4 subclone deficient for an
obligatory component of the HIF-1 heterodimer, HIF-1β, were de-
scribed previously [38]. The c4 cell line carries a mutated PAS region
of ARNT gene, causing impaired hypoxic induction of HIF binding
to DNA. Cells were grown at 37°C in Dulbecco’s modified Eagle’s
medium supplemented with 10% heat-inactivated fetal bovine se-
rum, 25 mM HEPES, and 2 mM L-glutamine (Life Technologies
Gibco BRL, Karlsruhe, Germany). For experimental hypoxia, cells
were subjected to a hypoxic microenvironment induced by flushing
a sealed incubator chamber with a gas mixture containing 1% O2
and 5% CO2 balanced with nitrogen.
Northern Blot Analysis, Probe Synthesis, and Quantitative
Reverse Transcription–Polymerase Chain Reaction
RNA isolation and Northern blot analysis were performed as pre-
viously described [3]. For probe synthesis, full-length cDNA clones
for uPA and uPAR were purchased from ATCC and amplified in
Escherichia coli JM109. Recombinant plasmids were isolated, and
cDNA inserts were excised and labeledwith [α-32P]dCTP (ICN, Irvine,
CA) by randompriming.Quantitative reverse transcription–polymerase
chain reaction has been performed as described elsewhere [39].
Western Blot Analysis
Pancreatic cancer cells were grown on 60-mmdishes.When 60%con-
fluent, cells were incubated in Opti-MEM for 12 hours, followed by
16 hours of hypoxic treatment, washed twice with phosphate-buffered
saline before lysis with 2× sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE) sample buffer (Bio-Rad, Hercules,
CA). Protein electrophoresis and transfer to nylon membranes were
performed as previously described [40]. Membranes were blocked
in 5% nonfat milk in Tris-buffered saline for 1 hour. Membranes
were incubated overnight with an anti uPAR-specific antibody (3932;
American Diagnostica, Greenwich, CT) at a 1:1000 dilution in Tris-
buffered saline and 0.05% Tween 20. The membrane was washed three
times with Tris-buffered saline and 0.05% Tween 20 and then incu-
bated with horseradish peroxidase–conjugated antirabbit IgG antibody
for 1 hour. Immunoreactive bands were detected by enhanced chemilu-
minescence. Antibodies specific for ERK1/2 and phospho-ERK were
purchased from Cell Signaling (Beverly, MA).
Analysis of Rac1 Activation
Affinity precipitation of active Rac1 was performed using the fusion
protein PAK-1 PBD, which binds specifically to the active, GTP-
bound forms of Rac1. MIA PaCA-2 and PANC-1 cells were cultured
in serum-free medium for 6 hours and exposed to 1.0% O2 for
16 hours. Control cultures were maintained in 21% O2. Cell extracts
were prepared in ice-cold radioimmunoprecipitation assay buffer con-
taining protease inhibitor cocktail and 1 mM sodium orthovanadate.
The extracts were incubated with 20 μg of PAK-1 PBD coupled to
glutathione-Sepharose for 60minutes at 4°C. The glutathione-Sepharose
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was washed three times and treated with SDS sample buffer to disso-
ciate the PAK-1 PBD and associated proteins. Cell extracts were sub-
jected to SDS-PAGE, and immunoblot analysis was performed to
detect Rac1. Samples of each cell extract were also subjected to immu-
noblot analysis before incubation with PAK-1 PBD to determine total
Rac1, uPAR, and tubulin, as a loading control.
Measurement of Apoptosis and Flow Cytometry
Apoptosis was induced by gemcitabine (kind gift from Eli Lilly,
Indianapolis, IN) which was diluted in phosphate-buffered saline
(PBS) to a 50-μM stock. Induction of apoptosis was measured by stain-
ing of fragmented DNA with Nicoletti buffer and flow cytometry as
described [41]. Experiments were performed at least three times in tripli-
cate, and values given are the mean of triplicates ± SD. A total of 2 × 105
cells per sample were used, and at least 1 × 104 cells were counted
(FACScalibur andCellQuest Software; BectonDickinson, San Jose, CA).
Preparation of Nuclear Extracts
Cells were harvested and centrifuged and nuclear extracts were pre-
pared as described previously [42]. The pellet was resuspended in four
packed cell volumes of buffer A (10 mM Tris-HCl (pH 7.8), 1.5 mM
MgCl2, 10 mM KCl), incubated on ice for 10 minutes, homogenized,
and centrifuged at 3,000 rpm for 5 minutes. The pellet was re-
suspended in three packed cell volumes of buffer C (0.42 M KCl,
20 mM Tris-HCl (pH 7.8), 1.5 mMMgCl2, 20% glycerol) and mixed
on a rotator at 4°C for 30 minutes. Nuclear fragments were pelleted
for 30 minutes at 14,000 rpm at 4°C. The supernatant was dialyzed
once against buffer Z (20 mM Tris-HCl (pH 7.8), 0.1 M KCl,
0.2 mM EDTA, 20% glycerol) for at least 3 hours at 4°C. The lysate
was centrifuged for 10 minutes at 14,000 rpm at 4°C and aliquoted.
Electrophoretic Mobility Shift Assay
Oligonucleotide probes were designed based on published human
sequences (GenBank Accession No. S78532; Figure W1) for the 5′-
region of the uPAR gene and purchased from Life Technology (Life
Technologies, Gaithersburg, MD). For electrophoretic mobility shift
assay (EMSA), an oligonucleotide was chosen, which contained the
first putative HIF binding site present within the uPAR promoter
(−34 to −39 bp). The binding site–specific sequence (coding strand)
of the wild type probe was 5′-AGA AGA CGT GCA GGG ACC
CC-3′, positions to −45 to −25 bp upstream of the start codon.
The sequence of the mutant probe was 5′-AGA AGA TTT GCA
GGG ACC CC-3′. Radioactive oligonucleotides were generated by
5′ end labeling using T4 polynucleotide kinase (Amersham Pharma-
cia Biotech, Piscataway, NJ). Binding reactions were done with 5 mg
of nuclear extracts, 0.1 mg of denatured calf thymus DNA, and 1 ng
of the radiolabeled probe (10,000 cpm). Supershift experiments were
done in the presence of a monoclonal anti–HIF-1α antibody H1a67
(Novus Biologicals, Littleton, CO). Electrophoresis was carried out
on a 5% nondenaturing polyacrylamide gel at 185 V in 0.3 × TBE
(1 × TBE is 89 mM Tris-HCl, 89 mM boric acid, and 5 mM EDTA)
at 4°C. Gels were vacuum dried and autoradiographed.
Nuclear Runoff Assay
To measure hypoxia specific up-regulation uPAR mRNA tran-
scription, we performed nuclear runoff assays as described [43]. After
cell lysis in 4 ml of lysis buffer (10 mM Tris (pH 7.4), 10 mM NaCl,
3 mM MgCl2, and 0.5% Nonidet P-40) and centrifugation, the nu-
clear pellet was resuspended in 200 μl of storage buffer (50 mM Tris
(pH 8.3), 5 mMMgCl2, 0.1 mM EDTA, and 40% glycerol) for sub-
sequent analysis. Nuclear runoff assays were initiated by incubating
200 μl of the nuclei with 200 μl of reaction buffer (5 μl of 1 M
dithiothreitol, and 2 μl of 100 mM ATP, CTP, GTP, and 10 μl of
10 mCi/ml [32P]UTP) for 30 minutes at 30°C. Subsequently, 40 μl
of 1 mg/ml DNase I and 1 ml of high salt buffer (0.5 M NaCl, 50 mM
MgCl2, 2 mM CaCl2, 10 mM Tris, pH (7.4)) were added and incu-
bated for 5 minutes at 30°C. After incubating samples for 30 minutes
(42°C) with 10 μl of proteinase K in 200 μl of SDS-Tris buffer con-
sisting of 5% SDS, 0.5 M Tris, pH 7.4, and 0.125 M EDTA, nuclear
RNAwas extracted and adjusted to 5 × 106 cpm/ml. Linearized uPAR
cDNA (100 μg) was denatured by incubating samples for 30 minutes
(23°C) in 0.2MNaOH and neutralized with 6× SSC. cDNA (5 μg per
sample) was slot blotted onto nylon membranes and UV cross-linked.
Membranes were hybridized at 42°Cwith 32P-labeledRNA samples for
24 hours, washed twice in 2× SSC at 65°C for 30minutes and incubated
for 30minutes at 37°Cwith 10mg/ml RNase A. After rinsing in 2× SSC
at 37°C for 1 hour, membranes were exposed at 80°C to Kodak XAR-5
films (Sigma-Aldrich, St. Louis, MO).
uPAR Promoter Activity
All deletionmutants were created by polymerase chain reaction (PCR)
using the promoter sequence (GenBank Accession No. S78532) as a
template. The constructs were designed to analyze all potential hyp-
oxia response elements (RCGTG) present in the uPAR promoter.
The following forward primers, containing an artificial Kpn I restric-
tion site, were used: 1 sense (1S) −870 to −849: TTT TTGGCTGAA
GTG TCT TTT; 2 sense (2S) −638 to −617: TTT TAA TGT AGG
TGC AAT GCC; 3 sense (3S) −523 to −502: GGC ACA GCA GGA
AGC AAA GCA. The reverse primers, to which an additional Bgl II
restriction site was attached were as follows: 1 antisense (1AS) −20
to +1: ACA GGA GCT GCC CTC GCG ACA; 2 antisense (2AS)
−77 to −56: ACA AAA CTG CCT CCT TCC TGA; 3 antisense
(3AS) −164 to −143: CCC CTC CTC CCG TAC GAA CC. For
site-directed mutagenesis of the HRE, the following reverse primer
was used −45 to −25: AGA AGA TTT GCA GGG ACC CC. The
PCR fragments were isolated, digested, and subcloned into the multi-
cloning site upstream of the luc+ reporter gene of the pGL3-Basic
vector (Promega Corporation, Madison, WI).
Luciferase Assays
Human pancreatic cancer and murine hepatoma cell lines (1 × 105
cells) were seeded in 60-mm dishes and cultured for 48 hours. Cells
were cotransfected with 3 μg of the different luciferase reporter gene
constructs along with 1 μg of pRL-CMV-Rluc (Promega). Briefly,
the plasmid mixture and 20 μl of Lipofectine reagent were mixed
in 200 μl of Opti-MEM (Life Technology, Rockville, MD) for
30 minutes at room temperature and were added to approximately
1 × 105 cells together with 800 μl of Opti-MEM per 35-mm dish.
After 6 hours of incubation, 1 ml of cell type–specific medium con-
taining 20% fetal bovine serum was added. At 24 hours after trans-
fection, the cells were either grown under hypoxic or normoxic
conditions for additional 12 hours. The cells were washed twice with
PBS and harvested in 500 μl of 1 × Passive Lysis Buffer (Promega)
followed by the measurement of the firefly and renilla luciferase
activities on a Lumat LB 9507 luminometer (Berthold, Bundoora,
Australia). The relative firefly luciferase activities were calculated by
normalizing transfection efficiency according to the renilla luciferase
activities. Fold activation of luciferase activity was calculated relative
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to control cells that were given the reference value of 1 as described
[44]. The experiments were performed in triplicate, and similar re-
sults were obtained from independent experiments.
In Vitro Invasion Assay and uPAR RNA Interference
The effect of hypoxia on the invasive potential of pancreatic can-
cer cells was tested in a Costar Transwell system with inserts contain-
ing a polycarbonate membrane with 8-mm pores (Corning Costar,
Corning, NY). Matrigel in serum-free medium (Matrigel; Collabora-
tive Biomedical Products, Bedford,MA) served as substrate for invasion.
Briefly, the Transwell invasion chambers were coated with 100 ml of a
1.0-mg/ml solution of Matrigel diluted in cold Dulbecco’s modified
Eagle’s medium and allowed to air dry for 12 hours. A total of 5 ×
104 MIA PaCa-2 cells dissolved in 100 ml of serum-free medium were
added to the upper well of the invasion chamber. The assay was done
in triplicates. Cells were either cultured under normoxic conditions
or subjected to a hypoxic microenvironment, both in the presence
and in the absence of 15 mg/ml blocking anti-uPAR antibody 3936
(American Diagnostica). After 24 hours, cells that invaded through
the Matrigel-coated membrane were fixed in Carnoy’s fixative (25%
acetic acid, 75% methanol) for 10 minutes and stained for 3 hours
in 1% toluidine blue, 1% sodium borate). After several washes in
tap water, the membranes were removed with a scalpel blade and ana-
lyzed on a microscopic slide. The invasive index was determined by
evaluating the total number of stained cells at the underside of the poly-
carbonate membranes under a microscope. For recombinant uPAR over-
expression, cells were transfected with a uPAR cDNA expression
plasmid (pEGFP-N1) or empty vector using Lipofectamine (Invitrogen,
Karlsruhe, Germany) and grown in a selection medium (1200 μg/ml
G418; Promega, Mannheim, Germany). The uPAR-RNAi vector was
also based on the pEGFP-N1 backbone. The uPAR sequence from
+77 to +98 was used as the target sequence, and for convenience, a
self-complimentary oligonucleotide was used. The uPAR sequence was
21 bases in length with a 9-base loop region and BamHI sites incorpo-
rated at the ends (gatcctacagcagtggagagcgattatatataataatcgctctccactg-
ctgtag). The oligonucleotide was self-annealed in 6× SSC buffer and
ligated onto the BamHI site of a linearized pEGFP-N1 vector plasmid.
The orientation of the insert was not relevant because the oligonucleo-
tides were self-complimentary. Bovine growth hormone poly-A termina-
tor served as a stop signal for RNA synthesis for all constructs. Moreover,
for uPAR knock-down experiments, pancreatic cancer cells were trans-
fected with siRNA (uPAR siRNA, sc-36781; Santa Cruz Biotechnology,
Heidelberg, Germany) according to the manufacturer’s instructions. As
control, a scrambled sequence siRNA was used (Santa Cruz Biotech-
nology), which specifically targets a sequence of human uPAR cDNA
(5′-GGTGAAGAAGGGCGTCCAA-3′), and a nonsilencing siRNA
(5′-AACCTGCGGGAAGAAGTGG-3′) was used as a control. Sup-
pression of uPAR protein was confirmed by Western blot analysis.
In Vivo Intravasation and Metastasis Assays
For intravasation, invasion, and metastasis assays in vivo, COFAL-
negative fertilized eggs from specific pathogen-free avian supply (SPAFAS,
Norwich, CT) were used and maintained at 37°C in a humidified in-
cubator for 8 days. Tumor cells, 75% confluent, were detached from
the cell culture dish with cell dissociation solution (Sigma), washed,
and resuspended in PBS. Usually, 5 × 105 cells were inoculated onto
a chorioallantoic membrane (CAM; so-called upper CAM) of a 9-day-
old chick embryo, in which an artificial air sac was created. For intra-
vasation assays, the CAM opposite to the inoculated tumor cells was
removed and immediately subjected to lysis buffer or frozen in liquid
nitrogen and stored at −80°C for further analysis.
For uPAR inhibition, 40 mg/ml neutralizing uPAR antibody 3936
(American Diagnostica), or for controls, an isotype-matched mouse–
antihuman γ-tubulin antidody (sc-17788; Santa Cruz Biotechnol-
ogy), was added ontopically on the CAM.
DNA Extraction and Human Alu PCR Amplification
Frozen tissue was homogenized in liquid nitrogen. Genomic DNA
was isolated using a DNA extraction kit (Gentra Systems, Minneapolis,
MN). Specific primers for a highly conserved human Alu sequence are
as follows: Alu-sense, 5′- ACG CCT GTA ATC CCA GCA CTT-3′;
and Alu antisense, 5′- TCG CCC AGG CTG GAG TGC A-3′, which
produced a band of 224 bp [27]. Polymerase chain reaction was per-
formed as described [27].
Statistical Analysis
Experiments were repeated at least three times. Results are ex-
pressed as means ± SE. Statistical significance was determined by Stu-
dent’s t test and Fisher’s exact test. P < .05 was considered to be
statistically significant.
Results
Hypoxia Induces Transcription of uPAR
Regulation of uPAR mRNA expression was tested in AsPC-1,
Capan-2, MIA PaCa-2, and PANC-1 cells. In addition, the mouse
hepatoma cell line Hepa-1c1c7 and its HIF-1β–deficient mutant
c4 subclone were used to analyze whether up-regulation of uPAR
mRNA is due to HIF activation [38]. Culturing the cells for 4, 8,
12, and 24 hours under hypoxic conditions resulted in a gradual
increase of uPAR mRNA in each cell line as examined by Northern
and Western Blot analyses (Figure 1A). Whereas Hepa-1c1c7 cells
strongly upregulated uPAR expression on hypoxic exposure, HIF-
1–deficient cells c4 showed only minimal activation as expected (Fig-
ure 1, A and B). Basal expression of uPAR mRNA was highest in the
undifferentiated cell line AsPC-1 and decreased proportionately to
the differentiation grade of the pancreatic cancer cells. The uPA
mRNA levels remained unchanged by hypoxia (data not shown).
To demonstrate functional activity of uPAR signaling in pancreatic
cancer cells, we analyzed the presence of endogenous ligands for
uPAR (Figure 1C ). First, we examined the basal level of activation
of ERK/MAPK and Rac1 in MIA PaCA-2 and PANC-1 cells that
were transferred for 16 hours to 1.0% O2. Both signaling proteins
were activated under hypoxic conditions (Figure 1C). Because aggres-
siveness of pancreatic carcinoma cell lines is exemplified by resistance
to gemcitabine standard chemotherapy, the percentage of apoptosis
induction correlated to the differentiation grade except for Capan-2
cells, thus paralleling the findings for uPAR mRNA up-regulation
(Figure 1D).
Because hypoxia is known to inhibit Cap-dependent transcription,
which causes stabilization of mRNA transcripts, we determined
whether the observed up-regulation of uPAR mRNA transcripts is
due to increased transcription or rather accumulation of mRNA
[45,46]. A nuclear runoff transcription assay was performed and eval-
uated by densitometry. Cells were cultured for 16 hours under hyp-
oxic or normoxic conditions. Whereas uPAR mRNA transcription
increased in all pancreatic cancer cell lines and parental hepatoma
cells, the mutant c4 subclone failed to upregulate uPAR transcription,
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Figure 1. (A) Hypoxia enhances uPAR expression in Northern blot and Western blot experiments. Human pancreatic cancer cell lines
AsPC-1, Capan-2, MIA PaCa-2, and PANC-1 together with the murine hepatoma cell line Hepa-1c1c7 and its mutated cell clone c4,
lacking functional HIF-1β, were cultured under normoxic or hypoxic conditions. After 24 hours, total RNA and protein were isolated,
size-fractionated, and transferred to membranes, which were hybridized in Northern blot experiments with a cDNA probe containing
500 bp of the human uPAR gene or in Western blot experiments with uPAR antibody 3932. The 7 S and γ-tubulin probes served as
controls to demonstrate equal loading. (B) Densitometry of hypoxia-induced uPAR expression was done as described in the Materials
and Methods section. The signal intensity of untreated normoxic control cells was measured and defined as a relative optical density of
1.0. On the basis of the individual signal intensity, the increase or the decrease of the relative optical density in comparison with un-
treated normoxic cells was determined. *P < .05. (C) Cell signaling factors known to be downstream of uPAR were analyzed. MIA PaCa-
2 and PANC-1 cells were cultured for 16 hours in 21% O2 (N) or 1.0% O2 (H). Cell extracts were affinity-precipitated and subjected to
immunoblot analysis to detect GTP-bound Rac1. The original cell extracts were studied by immunoblot analysis to determine total Rac1.
Cell extracts were also probed for phosphorylated ERK/MAPK and uPAR. (D) DNA fragmentation assay. AsPC-1, Capan-2, MIA PaCa-2,
and PANC-1 were incubated with 40 nM gemcitabine, and 72 hours later, apoptosis was determined by Nicoletti staining of fragmented
DNA and FACS analysis.
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as expected (Figure 2, A and B). Addition of actinomycin D (5 μg/ml),
which binds to DNA and inhibits RNA synthesis, resulted in a com-
plete suppression of transcriptional activity as analyzed in MIA PaCa-2
cells (Figure 2C ). mRNA kinetic analysis such as determination of
uPAR mRNA half-life in normoxia and in hypoxia did not result in
a different half-life (Figure 2B). Thus, hypoxia does not seem to affect
the stability of uPAR mRNA, suggesting that the observed increase in
uPAR mRNA levels by hypoxia was due to an increase in transcription
for the uPAR promoter.
HIF Regulates uPAR Promoter Activity
Sequence analysis of the human uPAR promoter (GenBank Ac-
cession No. S78532) revealed four putative binding sites for HIF.
Sequence analysis was done for the consensus HRE sequences (5′-
RCGTG-3′) [23] and the HRE motifs 5′-BACGTSSK-3′ (B =
G/C/T, S = G/C, and K = G/T) [47,48]. The first potential HIF
binding site, HRE-1 at position −34 to −39, the second site HRE-
2 at position −98 to −102, and the third binding site, HRE-3 at po-
sition −547 to −552, were identified on the sense strand. The fourth
binding site, HRE-4 at position −786 to −790, was located on the
antisense strand (Figure W1). To test whether the identified HRE
sequences within the HIF promoter contribute to regulation, we gen-
erated a series of deletion mutants, which were fused to the luciferase
reporter gene of the pGL3 basic vector (Figure 3A). MIA PaCa-2
cells were transfected with the PC 1.1, PC 2.2, PC 3.3, PC 1.3,
PC 3.1, or PC 3.2 constructs. After 36 hours, cells were exposed
to hypoxia, and luciferase assays were performed after additional
12 hours (Figure 3B). The wild type construct PC 1.1 and the mutant
construct PC 3.1 containing HRE-1 and HRE-2 showed an almost
200-fold induction of luciferase activity. In contrast, deletion of con-
sensus HRE-1 in PC 2.2, PC 3.3, PC 1.3, and PC 3.2 led to an al-
most complete down-regulation of promoter activity except of PC 2.2.
These minimal active construct still contains functional HRE-3 and
HRE-2 sites conferring a rest-activity of 44-fold. Because neither
HRE-2 alone in PC 3.2 nor HRE-3 alone in PC 1.3 showed activity,
the rest induction in PC 2.2 might be due to surrounding sequences.
To clearly demonstrate that HRE-1 is most important for hypoxia-
induced activation of the uPAR promoter, we generated two addi-
tional promoter constructs. In the PC 3.MUT construct, the putative
HIF binding site was mutated to ATTTG, the same mutation already
assayed by EMSA. The corresponding wild type construct is PC 3.1.
In MIA PaCa-2 cells, the wild type PC 3.WT construct showed a
nearly 200-fold increase in reporter gene activity; whereas the mutated
construct PC 3.MUTwas reduced to a 2.9-fold induction in reporter
gene activity (Figure 3C). To further investigate the role of hypoxic
induction of HIF, we transfected the Hepa-1c1c7 parental and its
derived HIF-1β–deficient subclone c4 with the PC3.1 vectors as well.
Whereas the parental cell line strongly upregulates transcription from
the uPAR promoter (approximately 130-fold, P < .01), the mutant
c4 cells exhibited only a slight increase (approximately 20-fold) in
the transcriptional rate, as expected, because HIF-binding activity
is blocked.
Figure 2. Hypoxia enhances uPAR transcription. (A) Top panel: Nuclear runoff assays comparing normoxic (N) and hypoxic (H) uPAR
transcription. Immediately after reaching 80% confluence, cells were exposed to normoxia or hypoxia for 16 hours, and nuclei were
prepared. [α-32P]UTP was incorporated in total RNA by in vitro transcription assays as described in the Materials and Methods section.
The radioactive-labeled RNA samples were hybridized to cDNA specific for uPAR, and autoradiography was performed. Lower panel:
The signal intensity of normoxic control cells was defined as a relative optical density of 1.0. On the basis of the individual signal in-
tensity, the increase or the decrease of the relative optical density in comparison with untreated normoxic cells was determined. *P <
.05. (B) Effect of hypoxia on mRNA stability in MIA PaCa-2 cells. RNA was isolated from cells cultured under normoxic and hypoxic
conditions after incubating with actinomycin D (5 mg/μl) for the indicated time. Quantitative reverse transcription–polymerase chain
reaction was performed and uPAR mRNA-quantified. Values of control cells were set at 100%. Each graph represents mean ± SEM
for three independent experiments.
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DNA-binding activity of HIF was tested by using a synthetic oligo-
nucleotide corresponding to the consensus HRE-1 at −34 to −39 bp
within the uPAR promoter by EMSA. Hypoxia-inducible factor 1–
binding activity was detectable as early as 1 hour after exposure of
MIA PaCa-2 cells to hypoxia and increased during the next 4 hours
(Figure 4). A supershift obtained by coincubation of monoclonal anti–
HIF-1α antibody and absence of binding activity on a 30-fold excess of
unlabeled wild type or labeled mutant oligonucleotide demonstrates
specificity of HIF-1 binding. Specificity is further underscored by a
30-fold excess of unlabeled mutated oligonucleotide for nonspecific
competition, which did not cause any difference in signal intensity.
Hypoxia Increases the Invasive Phenotype But Reduces Cell
Division In Vitro
Because uPAR might contribute to tumor invasion and metastasis,
we determined the role of hypoxia-mediated uPAR promoter activa-
tion on these processes using the Matrigel invasion assay. Pancreatic
cancer and hepatoma cells were added to the upper well of the inva-
sion chamber. After an initial growth period of 24 hours, the cells
were either cultured under normoxic conditions or subjected to a
hypoxic microenvironment, both in the presence and in the absence
of blocking anti-uPAR antibody (Figure 5, A–D). After 24 hours, the
cell fraction that invaded through the Matrigel-coated membrane
was fixed, stained, and analyzed by microscopy (Figure 5, A–D).
In general, the number of cells was lower in cell cultures of hypoxic
conditions when compared with cells cultured under normal oxygen
levels. However, the ratio of tumor cells crossing the Matrigel-coated
basement membrane was significantly higher under conditions of low
oxygen levels when compared with the invasiveness under normoxic
conditions. Upon addition of the neutralizing anti-uPAR antibody, a
strong reduction of tumor cell invasion was seen under both nor-
moxic and hypoxic culture conditions (Figure 5A). Urokinase-type
plasminogen activator receptor knock-down in a stably transfected
Figure 3. The consensus HRE within the uPAR promoter regulates
hypoxia-induced promoter activity. (A) Scheme of the human uPAR
promoter including putative consensus HREs. The black bars mark
putative HREs relative to the ATG codon. A series of deletion mu-
tants were constructed, and the length of the constructs relative to
the transcription start site is indicated. (B) MIA PaCA-2 cells were
transfected as described in the Materials and Methods section.
Transfected cells were maintained at 21°C and 1% O2 for 16 hours.
Luciferase reporter gene assays were performed, and luciferase ac-
tivities were normalized by using a dual-luciferase reporter system,
in which relative firefly luciferase activities were calculated thus nor-
malizing transfection efficiency according to the renilla luciferase
activities. Values represent means ± SD of n = 3 experiments per-
formed in duplicate. Statistical differences are indicated by asterisks
(*P < .05, Student’s paired t test). (C) MIA PaCa-2, Hepa-1, and c4
cells were transfected with the constructs indicated and analyzed
as described above.
Figure 4. Hypoxia-inducible factor binds to the consensus HRE in
uPAR promoter on hypoxia. MIA PaCa-2 cells were cultured under
normoxia or hypoxia for 1, 2, and 4 hours. Nuclear proteins were
harvested, and binding of a consensus HRE oligonucleotide of the
uPAR promoter was analyzed by EMSA as described in the Mate-
rials and Methods section. Control experiments were performed
with nuclear extracts from cells exposed 4 hours to normoxia or
1, 2, and 4 hours to hypoxia. For supershift and competition ex-
periments, the extract from cells cultured for 4 hours under hyp-
oxic conditions was used. The following reagents were added:
anti–HIF-1α antibody (Supershift), a 30-fold excess of unlabeled
consensus HRE oligonucleotide of the uPAR promoter (Specific
Competition), a labeled mutant consensus HRE oligonucleotide
of the uPAR promoter (Mutated Oligo), and a 30-fold excess of un-
labeled mutant consensus HRE oligonucleotide of the uPAR pro-
moter. C indicates constitutive; HIF-1, induced; N , nonspecific.
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MIA PaCa-2 cell clone also caused a decrease in tumor cell invasion,
whereas up-regulation of uPAR let to an increase in invasiveness
under conditions of low oxygen (Figure 5C ). Furthermore, siRNA-
based uPAR knock-down experiments resulted in reduced tumor cell
invasion under both normoxic and hypoxic culture conditions, when
compared with control treated cells (Figure 5D).
Angioinvasive Potential In Vivo Depends on Functional uPAR
Invasion of blood vessels is the first and rate-limiting process within
the metastatic cascade, and uPAR activity may be a critical component.
Therefore, we tested the angioinvasive potential of pancreatic cancer
cell lines under normoxic and hypoxic conditions in the presence or
absence of a neutralizing uPAR antibody in the CAM assay using
fertilized chicken eggs. AsPC-1, Capan-2, MIA PaCa-2, PANC-1,
Hepa-1c1c7, and c4 cells were inoculated on the CAM of 9-day-
old chick embryos. For detecting intravasation, genomic DNA from
the opposite CAM was examined for the expression of human Alu
sequences by PCR (Figure 6A). Angioinvasion was seen under nor-
moxic conditions in all cell lines examined, which could be strongly
increased by hypoxia. We further analyzed whether experimental in-
duction of HIF might change the angioinvasive potential. Because
induction of hypoxia with cycloheximide was lethal for most chicken
eggs, we applied intermittent hypoxia ontopically by flushing the
upper CAM with an anoxic gas mixture for 60 minutes every 4 hours.
Figure 5. uPAR inhibition reduces tumor cell invasion. (A) MIA PaCa-2 cells were cultured under normoxic or hypoxic conditions as
indicated. Invasion was measured by using a reconstituted basement membrane in Costar Transwell inserts containing a polycarbonate
membrane with 8-mm pores in the presence of Matrigel as described in the Materials and Methods section. At 24 hours after incuba-
tion, cells invading through the semipermeable membrane in the presence or absence of blocking anti-uPAR antibody (uPAR-NAB) were
fixed and stained. The invasion score was then determined by counting the total number of stained cells at the underside of the poly-
carbonate membranes under a microscope. Error bars, SEM across three experiments. (B) An example of the underside of a membrane
showing invading cells by light microscopy is displayed for cells treated with normoxia or hypoxia as indicated. (C) Stably transfected
MIA PaCa-2 cells expressing uPAR-siRNA or uPAR full-length cDNA were also cultured 24 hours under low oxygen levels. Clearly, the
uPAR expression was associated with tumor cell invasion. Overexpression of uPAR could be reverted by the addition uPAR-NAB. (D)
siRNA treatment reduced tumor cell invasion in all cell lines both under normoxic and hypoxic culture conditions. For control treatment,
a scrambled siRNA oligonucleotide was used. Values represent means ± SD of n = 3 experiments performed in duplicate (*P < .05,
Student’s paired t test; #P < .05 compared with hypoxia [A] or uPAR overexpression [D]).
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This treatment led to increased angioinvasion in chicken eggs (Fig-
ures W2 and W3). To further elucidate whether angioinvasion was
due to up-regulation of uPAR activity, we ontopically added a neu-
tralizing uPAR antibody resulting in reverted blood vessel invasion
below the values of untreated cells (Figure 6B), whereas addition of
an isotype-matched control antibody did not affect tumor cell invasion
(data not shown). Therefore, these data clearly demonstrate involve-
ment of HIF in uPAR-mediated angioinvasion.
Discussion
Hypoxia is considered as a physiological condition in growth of
human solid tumors, and the protease systems of uPA/uPAR and me-
talloproteinases were previously shown to participate in metastatic
disease progression. More recent studies suggest that concomitant ex-
pression of uPA and uPAR is indispensable for tumor intravasation
[27], including our own data demonstrating that hypoxia induces
HIF expression in experimental pancreatic cancer [49] and in tumors
of patients [3]. These data may be important for future therapeutic
approaches because local invasion and early metastatic tumor pro-
gression are still the most challenging clinical features of pancreatic
cancer. Our present study provides the link by which hypoxia most
likely increases local aggressiveness and systemic tumor dissemina-
tion. Using established human pancreatic cancer cell lines, we found
that the basal expression of uPAR under normoxic conditions was
highest in undifferentiated, therapy-resistant cells and could be fur-
ther induced by hypoxia. These data may correspond to the fact that
undifferentiated tumor cells exhibit a more aggressive phenotype and
metastasize more frequently when uPAR is upregulated [5,50,51].
Our studies provide evidence that uPAR mRNA expression is only
induced in cells carrying functional HIF but not in cells deficient in
HIF, as we conclude from a parental and a derived HIF-deficient
subclone of a hepatocellular carcinoma [52,53], which failed to up-
regulate uPAR in response to low oxygen levels. These results are
in line with a recent report describing increased expression of uPAR
on hypoxia in breast cancer cells, although the underlying mecha-
nisms were not provided [54]. The observed hypoxia-induced activa-
tion of uPAR is not due to mRNA stabilization but to enhanced
transcription, as we found in nuclear runoff assays. Thus, this finding
strengthens our hypothesis that expression of the uPAR gene is con-
trolled by HIF.
Despite significant progress has been made in cancer biology, only
little is known why some cancer cells do metastasize while others do
not, even so these cell populations likely descended from an iden-
tical pool of transformed cells [55,56]. One hypothesis is that a
specific transient regional tumor microenvironment of low oxygen
induces a distinctive epigenetic gene expression profile in a subset
of cells, which likely causes selection of more aggressive cell clones
[14,51,57–59]. A direct link between hypoxia-induced HIF and reg-
ulation of uPAR has never been shown. All we know so far is that the
protease systems of uPA/uPAR and metalloproteinases participate in
the metastatic disease progression, which is dependent on hypoxia.
More recent studies suggest that concomitant expression of uPA
and uPAR is indispensable for tumor intravasation [27]. Despite
these alarming reports reflecting an important function of uPAR in
metastasis, regulation of the promoter region in a hypoxic tumor mi-
croenvironment is only marginally understood. Therefore, we created
uPAR promoter fragments and confirmed by reporter assays that in-
deed high induction of uPAR on hypoxia is strictly dependent on the
presence of wild type HREs with maximal transcriptional regulatory
activity localized at the first HRE closely upstream to the ATG start
codon. Our observation is accordant to results of Soravia et al. [36],
which found the highest basal transcriptional activity of the uPAR
promoter within the first −181 bp upstream of the transcription ini-
tiation site. Our analysis of the promoter region of the human uPAR
gene revealed four potential HREs (RCGTG) within the first 1000 bp
upstream to the ATG start codon. Two HREs (ACGTG) were in
5′–3′ orientation, whereas the other two were either TCGTG or ori-
ented in 3′–5′ direction. We deleted all putative HREs alone or in
combination by PCR mutagenesis, cloned them in front of a luciferase
reporter gene, and tested transcriptional activity of the constructs. By
this way, it became apparent that the HRE at position −35 to −39 bp
is the main regulatory HRE sequence, and its mutation silenced the
transcriptional activity even so some transcriptional activity was detect-
able in deletion mutants not carrying this HRE (−35/−39 bp). There-
fore, we conclude that regulation of the uPAR gene expression is under
the control of the HRE positioned closely upstream of the translation
initiation site.
The importance of uPAR expression in metastasis was further tested
using the CAM assay of fertilized chick embryos, which was used
to study whether any of these observations had an in vivo relevance
Figure 6. uPAR inhibition blocks angioinvasion after hypoxia in vivo.
(A) Cells were inoculated onto the dropped CAMs of chicken em-
bryos. Three days later, the lower CAMs were excised, genomic
DNA was isolated, and 1 μg of DNA was used to amplify human
Alu sequences in the presence of [32P]-dCTP. Polymerase chain
reaction products were analyzed by PAGE and visualized by autora-
diography. (B) Inhibition of intravasation by a neutralizing uPAR an-
tibody. Inoculated tumor cells were repeatedly flushed with an
anoxic gas mixture for the induction of hypoxia. For uPAR inhibition,
40 mg/ml neutralizing uPAR antibody was added ontopically (Mate-
rials and Methods section). Alu sequences were analyzed as de-
scribed above. All experiments were repeated at least three times
with 10 eggs in each group. Angioinvasion was calculated relative
to normal untreated cells, which were set as 1. *P < .05, compared
hypoxia versus normoxia as well as hypoxia versus uPAR inhibition.
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for tumor biology. Because it has been suggested that the rate-limiting
step for metastasis is angioinvasion and that this process is critically
dependent on uPAR expression, we inoculated various pancreatic can-
cer cell lines, parental HEP1a1c cells as well as its mutant clone c4.
Inhibition experiments were performed with a neutralizing uPAR anti-
body. The angioinvasive potential was found to be highly dependent
on uPAR expression. Intermittent hypoxia increased angioinvasion in
most cell lines but not in the HIF-deficient c4 cells. Furthermore, addi-
tion of a neutralizing anti-uPAR antibody suppressed the angioinvasive
phenotype below the levels of normoxic cultures. It is noteworthy that
well-differentiated cell lines with low constitutive uPAR expression
hardly invaded in chicken blood vessels, whereas low differentiated
cell lines expressing higher uPAR levels exhibited a higher constitutive
angioinvasive potential corresponding to the finding that undifferenti-
ated tumor cells exhibit a more aggressive phenotype and metastasize
more frequently [5]. In line with our results, siRNA toward HIF has
been shown to block invasion of a colon carcinoma cell line using
in vitro Matrigel assays [26].
The functional relevance of uPAR signaling has to be analyzed in
the context of its two principal ligands, uPA and its inhibitor plas-
minogen activator inhibitor 1 (PAI-1). PAI-1 has been shown to be
regulated by HIF-1 as well with an up-regulation under hypoxic con-
ditions similar to the up-regulation of uPAR [18,47,60,61]. Thus,
HIF-1 may act as a “Janus-faced” or “bicephalous” transcription fac-
tor, which regulates both proinvasive and anti-invasive proteins. This
is in line with the finding that HIF-1 may promote proapoptotic and
antiapoptotic molecules as well, suggesting a potential to regulate cell
growth bidirectionally [62–64]. This HIF may differentially activate
its target genes dependent on the specific cell type or organ [62,64].
In summary, our studies demonstrate that hypoxic uPAR mRNA
expression is under the control of the transcription factor HIF and
highly suggest that exposure of pancreatic cancer cells to low oxygen
levels increases the angioinvasive phenotype by regulating uPAR ex-
pression. This axis defines a master regulator of hypoxic tumor cell
invasion and may be important for future therapeutic concepts.
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Figure W1. Sequence of the human uPAR promoter (S78532). A gene bank search was performed for hypoxia response elements within
the uPAR promoter. Four putative HREs (5′-RCGTGC-3′) were identified in the uPAR promoter (NCBI Accession No. S78532). The de-
tailed sequence, with HRE and the translation initiation site (ATG with arrow), is indicated; bold sequences indicate putative HREs. The
first HRE-1 (−34 to −39), the second HRE-2 (−98 to −102), and the third HRE-3 (−547 to −552) are located on the sense strand; the
fourth HRE-4 (−786 to−790) is located on the antisense strand. Sense primers used for creating deletion mutants are indicated: 1 sense
(1S); 2 sense (2S); and 3 sense (3S). Reverse primers were as follows: 1 antisense (1AS); 2 antisense (2AS); and 3 antisense (3AS). The
first 944 bp of the promoter sequence are shown.
Figure W2. Angioinvasion is dependent upon uPAR expression
in vivo. A total of 1 × 106 human cancer cells were inoculated on
10CAMsof chicken embryos. Threedays later, the lowerCAMswere
excised, and genomic DNA was isolated and tested for human Alu
sequences (see Materials and Methods section). Inhibition of uPAR
geneexpressionbysiRNA resulted in reducedangioinvasion,whereas
recombinant overexpression of uPAR increased tumor cell invasion.
This increase was reducible by the addition of 40 mg/ml neutralizing
uPAR antibody (NAB) biut was unchanged on the addition of an equal
amount of an unspecific isotype matched antibody (IMAB). *P < .05
compared with untreated control cells.
Figure W3. Hypoxia-induced angioinvasiobn by upregulation of uPAR expression through HIF-1 activation. Cell migration from the pri-
mary tumor and invasion into adjacent blood vessels is a multistep process leading to metastasis in carcinomas. Invasion requires a
proteolytic modification of the extracellular matrix and tumor cell migration. Hypoxia-inducible factor activates proteolysis by the induc-
tion of uPAR. (A) Normal epithelial cells are located on a basement membrane with close contact to the ECM. Under low-oxygen condi-
tions (hypoxia), HIF-1 is active (B) and induces the expression of uPAR (C). This pathway might account for increased angioinvasion (D),
which represents the central and rate-limiting step of the metastatic cascade.
